Dual inhibition of PKC and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

被引：0
|
作者：
Carita, Guillaume
Leitz, Estelle Frisch Dit
Dahmani, Ahmed
Raymondie, Chloe
Cassoux, Nathalie
Piperno-Neumann, Sophie
Nemati, Fariba
Halilovic, Ensar
Jeay, Sebastien
Wylie, Andrew
Emery, Caroline
Roman-Roman, Sergio
Schoumacher, Marie
Decaudin, Didier
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-3027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3027
引用
收藏
页数：3
相关论文
共 44 条
  • [41] Dual Inhibition of PI3K and mTORC1/C2 by PKI-587 (PF-05212384) as a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease and Its Effect on AKT-Signaling
    Freitag, H.
    Briest, F.
    Christen, F.
    Grass, I
    Lewens, F.
    Siegmund, B.
    Grabowski, P.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 80 - 80
  • [42] DUAL INHIBITION OF MTORC1/C2 AND MEK PATHWAY IS SYNERGISTIC IN MULTIPLE HUMAN MODELS OF PEDIATRIC LOW-GRADE GLIOMA INCLUDING A NOVEL PATIENT-DERIVED NF1 PILOCYTIC ASTROCYTOMA CELL LINE
    Arnold, Antje
    Yuan, Ming
    Rodriguez, Fausto
    Eberhart, Charles
    Raabe, Eric
    NEURO-ONCOLOGY, 2018, 20 : 115 - 116
  • [43] Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc
    Nishida, Yuki
    Ishizawa, Jo
    Ruvolo, Vivian
    Kojima, Kensuke
    Montoya, Rafael Heinz
    Daver, Naval G.
    Lesegretain, Arnaud
    Shacham, Sharon
    Andreeff, Michael
    BLOOD, 2019, 134
  • [44] Preclinical study of cytotoxicity and predictive markers of response to dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 with or without paclitaxel or nab-paclitaxel as a new therapeutic strategy in pancreatic cancer cell lines.
    Loaiza-Bonilla, Arturo
    Kittaneh, Muaiad
    Amado, Victor Daniel Guardiola
    Kovacs, Krisztina
    Merchan, Jaime R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345